Definium Therapeutics Appoints Roger Adsett to Board of Directors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 17h ago
0mins
Definium Therapeutics (DFTX) announced the appointment of Roger Adsett to its Board of Directors. Adsett currently serves as COO of Insmed (INSM). The appointment increases the board from six to seven directors.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like DFTX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on DFTX
Wall Street analysts forecast DFTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DFTX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 16.840
Low
Averages
High
Current: 16.840
Low
Averages
High
About DFTX
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Definium Appoints Roger Adsett to Board of Directors to Drive Growth
- Leadership Expansion: Definium Therapeutics announces the appointment of Roger Adsett to its Board of Directors, leveraging over 20 years of experience in biopharmaceuticals to drive the company's success in three anticipated Phase 3 trials in 2026.
- Strategic Optimization: Adsett's proven track record at Insmed, particularly in launching ARIKAYCE® and BRINSUPRI®, indicates he will provide valuable commercial execution capabilities to enhance Definium's market impact in mental health treatments.
- Commitment to Scientific Rigor: Adsett expressed admiration for Definium's commitment to scientific rigor in mental health, indicating his dedication to translating clinical research into valuable therapies, thereby strengthening the company's leadership position in the industry.
- Educational Background and Experience: With an MBA from the Wharton School at the University of Pennsylvania and a bachelor's degree in English and economics from Bucknell University, Adsett's extensive educational and professional background will provide robust support for Definium's strategic development.

Continue Reading
Doseology Sciences Partners with McKinney to Enhance Regulatory Compliance Strategy
- Market Growth: The consumer healthcare market is projected to reach $362 billion in 2026, prompting companies to prioritize regulatory certainty as a key component of their business strategies in a competitive landscape.
- Increased M&A Activity: A 12% rise in merger activity is anticipated in 2026 as companies pursue acquisitions to enhance technological efficiency, underscoring the critical need for thorough due diligence in navigating federal risks.
- Strategic Partnership: Doseology has partnered with McKinney Regulatory Science Advisors to expedite product development and market access through expert FDA compliance consulting, ensuring alignment with regulatory expectations.
- Market Outlook: Doseology aims to enter a global pouch market expected to exceed $69.46 billion by 2032, advancing towards commercialization with a clear regulatory strategy and secured manufacturing infrastructure.

Continue Reading








